In contrast, YY1—an established regulator of tumor immunomodulation—exhibited consistent predictive power: elevated YY1 expression was associated with shorter OS in melanoma (Figure 1B) and glioblastoma (Figure 1C) patients receiving anti‐PD‐1 therapy. Here, YY1 is linked to melanoma.